Birdwatch Note
2023-03-12 17:14:05 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
The FDA publishes the 503B Bulks List, a list of active pharmaceutical ingredients. Some of the items on this list were recommended to be included, but none received adequate support, meaning that these compounds have NOT been rebranded as “substances.” https://www.fda.gov/media/94164/download https://www.federalregister.gov/documents/2022/01/27/2022-01558/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
Written by 873F3C7468C0790B61E29ECBA910F835731B69126F882CF1F21456FC66F41E7B
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1634675692981092353
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1634966000226402304
- noteId - 1634966000226402304
- participantId - 873F3C7468C0790B61E29ECBA910F835731B69126F882CF1F21456FC66F41E7B
- noteAuthorParticipantId -
- createdAtMillis - 1678641245309
- tweetId - 1634675692981092353
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The FDA publishes the 503B Bulks List, a list of active pharmaceutical ingredients. Some of the items on this list were recommended to be included, but none received adequate support, meaning that these compounds have NOT been rebranded as “substances.” https://www.fda.gov/media/94164/download https://www.federalregister.gov/documents/2022/01/27/2022-01558/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-03-12 17:14:05 UTC (1678641245309) |
1969-12-31 23:59:59 UTC (-1) |
2023-03-13 02:08:35 UTC (1678673315039) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-03-12 18:45:44 -0500 | 081E40DD9D6FE456EA6E427DDDD80A03269B6088B0556BA2D5FA37D97E890EDE | Rating Details |
2023-03-12 14:09:49 -0500 | 3922021E2B4C1A4B610B8FAFE0447925B4441B7A397CBAE1E446B9DE65C2A8E3 | Rating Details |
2023-03-12 13:07:03 -0500 | 45060ED935D102E05C21C743FE433C0B17B27D8FCF69CED01A2AD3F9AB2815B1 | Rating Details |
2023-03-12 13:18:02 -0500 | 464F514091F013106E190C712492FDDD7A2F35D38B0E762F31374CC21B9FD858 | Rating Details |
2023-03-12 13:14:04 -0500 | 60CA16F021BFF5F46E779702FDD20F5F5038764BDB8C232B3E5EB692C88A3F38 | Rating Details |
2023-03-12 17:04:14 -0500 | 77970E3BCBC3225621F0B02418F03B8FF013C6AE18E33EFF939C51AD5AE32792 | Rating Details |
2023-03-12 18:09:35 -0500 | B289B7B9A72A2B21A5016714B5CFECC892B67D4EF528AD49D229201250F7B83A | Rating Details |
2023-03-12 16:26:05 -0500 | B5FEE1C7F02671E2466AE0184315222BE9F827034DA0D608839BE86F8B7D554A | Rating Details |
2023-03-14 06:49:00 -0500 | Rating Details | |
2023-03-13 11:02:19 -0500 | Rating Details | |
2023-03-13 10:36:15 -0500 | Rating Details | |
2023-03-13 10:23:34 -0500 | Rating Details | |
2023-03-13 10:14:11 -0500 | Rating Details | |
2023-03-13 10:01:46 -0500 | Rating Details | |
2023-03-13 09:51:21 -0500 | Rating Details | |
2023-03-13 09:37:03 -0500 | Rating Details | |
2023-03-13 09:22:31 -0500 | Rating Details | |
2023-03-13 09:21:49 -0500 | Rating Details | |
2023-03-13 08:59:25 -0500 | Rating Details | |
2023-03-13 08:58:51 -0500 | Rating Details | |
2023-03-13 08:48:15 -0500 | Rating Details | |
2023-03-13 08:10:50 -0500 | Rating Details | |
2023-03-13 08:05:31 -0500 | Rating Details | |
2023-03-13 04:31:21 -0500 | Rating Details | |
2023-03-16 12:19:38 -0500 | Rating Details | |
2023-03-15 23:05:50 -0500 | Rating Details | |
2023-03-21 22:56:16 -0500 | Rating Details | |
2023-04-05 15:30:47 -0500 | Rating Details | |
2023-03-13 10:01:46 -0500 | Rating Details | |
2023-03-13 08:58:51 -0500 | Rating Details | |
2023-03-13 09:37:03 -0500 | Rating Details | |
2023-03-12 17:04:14 -0500 | Rating Details | |
2023-03-15 23:05:50 -0500 | Rating Details | |
2023-03-16 12:19:38 -0500 | Rating Details | |
2023-03-13 10:36:15 -0500 | Rating Details | |
2023-03-13 08:10:50 -0500 | Rating Details | |
2023-03-12 16:26:05 -0500 | Rating Details | |
2023-03-13 04:31:21 -0500 | Rating Details | |
2023-03-12 13:07:03 -0500 | Rating Details | |
2023-03-13 08:48:15 -0500 | Rating Details | |
2023-03-12 18:45:44 -0500 | Rating Details | |
2023-03-12 13:14:04 -0500 | Rating Details | |
2023-03-13 08:59:25 -0500 | Rating Details | |
2023-03-12 14:09:49 -0500 | Rating Details | |
2023-03-13 10:14:11 -0500 | Rating Details | |
2023-03-12 13:18:02 -0500 | Rating Details | |
2023-03-13 09:21:49 -0500 | Rating Details | |
2023-03-12 18:09:35 -0500 | Rating Details | |
2023-03-13 08:05:31 -0500 | Rating Details | |
2023-03-13 11:02:19 -0500 | Rating Details | |
2023-03-14 06:49:00 -0500 | Rating Details | |
2023-03-13 09:22:31 -0500 | Rating Details | |
2023-03-21 22:56:16 -0500 | Rating Details | |
2023-03-13 09:51:21 -0500 | Rating Details | |
2023-03-13 10:23:34 -0500 | Rating Details | |
2023-04-05 15:30:47 -0500 | Rating Details |